Research News

---

Topic: Hormonal Therapies (view all topics)

Tags for topic Hormonal Therapies:

• After surgery (also called "adjuvant")
• Arimidex
• Aromasin
• Aromatase Inhibitors
• Before surgery (also called "neoadjuvant")
• Evista
• Fareston
• Faslodex
• Femara
• Not applicable (no surgery)
• Planning Hormonal Therapy
• Prophylactic (to lower risk if you've never been diagnosed with breast cancer)
• Selective Estrogen Receptor Modulators
• Tamoxifen

View articles by month and year

• Do Antidepressants Interfere with Tamoxifen? Results Unclear

  Published on May 30, 2009 at 12:00 am

  • Tags: Tamoxifen, After surgery (also called "adjuvant"), Prophylactic (to lower risk if you've never been diagnosed with breast cancer), and Planning Hormonal Therapy

  While the results aren't definitive, one of two new studies suggests that women who take tamoxifen at the same time as the antidepressant medicines Prozac or Paxil may not get the full benefits of tamoxifen.

• Tamoxifen and Zoladex Offer Same Recurrence Risk Reduction

  Published on February 26, 2009 at 12:00 am

  • Tags: Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  A new international study has found that tamoxifen and Zoladex (chemical name: goserelin) work about the same to lower the risk of breast cancer coming back.

• Femara May Improve Survival Compared to Tamoxifen

  Published on December 16, 2008 at 12:00 am

  • Tags: Femara, Tamoxifen, and After surgery (also called "adjuvant")

  For the first time, research suggests that the aromatase inhibitor Femara improves overall survival compared to tamoxifen.

• Aromasin Slightly Better than Tamoxifen at Reducing Recurrence Risk

  Published on December 15, 2008 at 12:00 am

  • Tags: Aromasin, Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Research shows that the aromatase inhibitor Aromasin reduces the risk of the cancer coming back somewhat better than tamoxifen in post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.

• Aromatase Inhibitors Slightly Better Than Tamoxifen for Postmenopausal Women

  Published on December 12, 2008 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), Aromatase Inhibitors, and Planning Hormonal Therapy

  A review of a number of studies confirms that aromatase inhibitors reduce the risk of early-stage, hormone-receptor-positive breast cancer coming back better than tamoxifen in post-menopausal women.

• Hormonal Therapy Side Effects Linked to Lower Risk of Recurrence

  Published on October 29, 2008 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  New research suggests a link between hormonal therapy side effects (hot flashes, night sweats, joint pain) and a reduced risk of breast cancer coming back.

• Zoladex May Help Reduce Risk of Recurrence

  Published on October 10, 2008 at 12:00 am

  • Tags: Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  After surgery and other treatments for hormone-receptor-positive early-stage breast cancer in premenopausal women, treatment with the hormonal therapy medicine Zoladex (chemical name: goserelin) can lower the risk of the cancer coming back and improve overall prognosis.

• Arimidex Doesn’t Seem to Cause Thinking or Memory Problems

  Published on September 3, 2008 at 12:00 am

  • Tags: Arimidex and After surgery (also called "adjuvant")

  A small study shows that women who took the aromatase inhibitor Arimidex (chemical name: anastrozole) for 2 years didn't have any more thinking and memory problems than women who took a placebo pill for 2 years.

• Zometa Helps Keep Bones Strong During Hormonal Therapy

  Published on August 20, 2008 at 12:00 am

  • Tags: Arimidex, Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Zometa helps keep bones strong in pre-menopausal women getting hormonal therapy to treat hormone-receptor-positive, early-stage breast cancer.

• Zometa May Reduce Recurrence Risk

  Published on June 2, 2008 at 12:00 am

  • Tags: Arimidex, Tamoxifen, and After surgery (also called "adjuvant")

  New research suggests that Zometa, a bone-strengthening medicine, may help lower the risk of breast cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer who aren't being treated with chemotherapy.